Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNI versus ARB after primary valvular regurgitation surgery for residual left ventricular remodeling
ChiCTR2000038895Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sacubitril + valsartan in Left ventricular remodeling (LVR), aortic insufficiency (AI) and mitral regurgitation (MR) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Left ventricular ejection fraction and Left ventricular end-diastolic dimension. Started Oct 2020; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
Left ventricular remodeling (LVR)aortic insufficiency (AI)mitral regurgitation (MR)
Beyond the preview
Go deeper on ChiCTR2000038895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038895.